title: Fertility preservation in breast cancer patients.
abstract: Breast cancer is the most common malignant tumor in women of reproductive age, and is characterized by a high survival rate owing to improved antineoplastic treatments. Young survivors face the prospect of a diminished fertility as a consequence of the gonadotoxic chemotherapy, and many are seeking ways to preserve their fertility. Embryo and/or oocyte cryopreservation following controlled ovarian stimulation is currently the fertility preservation method of choice, but breast cancer patients may have contraindications to exogenous gonadotropin administration and may not have enough time to undergo ovarian stimulation prior to chemotherapy. Fortunately, many other options are available for these women, such as the letrozole-follicle-stimulating hormone ovarian stimulation protocol, in vitro maturation of oocytes and ovarian tissue cryopreservation. In this review, we discuss the benefits and disadvantages of the different fertility preservation techniques that can be offered to breast cancer patients.
authors.affiliation: Service de Gynécologie-Obstétrique, Hôpital Hôtel-Dieu de France, Beyrouth, Liban.
authors.forename: Hady
authors.initials: H
authors.lastname: El Hachem
authors.forename: David
authors.initials: D
authors.lastname: Atallah
authors.forename: Michael
authors.initials: M
authors.lastname: Grynberg
mesh_terms: D015415:Biomarkers; D001943:Breast Neoplasms / Q000150:complications / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D059247:Fertility Preservation / Q000379:methods; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D009154:Mutation; D016649:Primary Ovarian Insufficiency / Q000209:etiology / Q000517:prevention & control
chemical_list: D015415:Biomarkers
keywords: breast cancer; embryo/oocyte cryopreservation; fertility preservation; in vitro maturation